CDR-LIFE AG


Associated tags: Paratriathlon, Boehringer Ingelheim, Geographic atrophy, MHC, Therapy, Biotechnology, Vaccine, Patient, Severe cognitive impairment, Fine chemical, Doctor of Philosophy, Pharmaceutical industry

Locations: GA, SCHLIEREN, CH, SWITZERLAND, MASSACHUSETTS, KITA, CALIFORNIA

CDR-Life to Present Tumor Targeting Capabilities of M-gager® Platform at the TCR-Based Therapies for Solid Tumors Summit

Retrieved on: 
Tuesday, April 23, 2024
TCE, MHC, Antibody

ZÜRICH, Switzerland, April 23, 2024 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced a presentation on its proprietary antibody-major histocompatibility complex (MHC) technology for the development of highly specific T-cell engagers (TCE) at the TCR-Based Therapies for Solid Tumors Summit, occurring April 23-25 in Boston, Massachusetts.

Key Points: 
  • ZÜRICH, Switzerland, April 23, 2024 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced a presentation on its proprietary antibody-major histocompatibility complex (MHC) technology for the development of highly specific T-cell engagers (TCE) at the TCR-Based Therapies for Solid Tumors Summit, occurring April 23-25 in Boston, Massachusetts.
  • The presentation will discuss how antibodies targeting tumor peptides on the MHC enable T-cells access to an untapped reservoir of intracellular tumor antigens and will highlight the M-gager® technology’s ability to leverage the potency, versatility and manufacturability of antibodies to revolutionize cancer immunotherapy.

CDR-Life Unveils Results on T-Cell Engagers Targeting Hard-to-Treat Solid Tumors at AACR 2024

Retrieved on: 
Friday, April 5, 2024
Cell, Trichloroethylene, Patient, Lung, Epitope, Breast, KK, Allele, AACR, Cancer, Antibody, TCE, Therapy, Peptide, Vaccine

Identifying a TCE against the KK-LC-1 peptide on HLA-A*01 will provide an option for patients that do not benefit from the more common HLA-A*02 targeting therapeutics currently in development.

Key Points: 
  • Identifying a TCE against the KK-LC-1 peptide on HLA-A*01 will provide an option for patients that do not benefit from the more common HLA-A*02 targeting therapeutics currently in development.
  • However, high levels of similar off-target peptides presented in healthy tissues make targeting the KK-LC-1/HLA-A*01 challenging.
  • CDR-Life’s data gathered on pMHC TCE antibodies with high specificity towards HLA-A*01 restricted KK-LC-1 epitopes demonstrate the antibodies’ promising anti-tumor activity and specificity for KK-LC-1/HLA-A*01 positive tumors.
  • In vitro studies showed significantly higher TCE-dependent T-cell activation towards cells presenting the target peptide compared to the risk peptides.

CDR-Life Announces FDA Clearance of IND Application for CDR404 for Treatment of Solid Tumors

Retrieved on: 
Tuesday, January 23, 2024
Investigational New Drug, NSCLC, Cancer, IND, Food, Lung cancer, FDA, Pharmaceutical industry

ZURICH, Switzerland, Jan. 23, 2024 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced the clearance of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for CDR404, its lead program in development as a precision immunotherapy for solid tumors.

Key Points: 
  • ZURICH, Switzerland, Jan. 23, 2024 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced the clearance of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for CDR404, its lead program in development as a precision immunotherapy for solid tumors.
  • “CDR404 holds the potential to become the off-the-shelf therapy for multiple cancers expressing MAGE-A4 with high unmet need, including non-small cell lung cancer (NSCLC),” said Christian Leisner, Ph.D., Chief Executive Officer at CDR-Life.
  • “We are thrilled to achieve this milestone and are continuing to advance several additional programs leveraging our M-gager® technology against promising intracellular cancer targets with the goal of improving patient lives.”
    The company anticipates initiating Phase 1 trial enrollment in the coming months.

CDR-Life Announces First Patient Dosed in Phase 1 Study with Boehringer Ingelheim Evaluating Potential Treatment for Geographic Atrophy

Retrieved on: 
Wednesday, December 6, 2023
Pharmacokinetics, Ageing, Patient, Geographic atrophy, AMD, Safety, Retina, Boehringer Ingelheim, Pathology, Pharmaceutical industry

ZÜRICH, Switzerland, Dec. 06, 2023 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced that the first patient has been dosed in the Phase 1 trial of BI 771716 for the treatment of geographic atrophy (GA).

Key Points: 
  • ZÜRICH, Switzerland, Dec. 06, 2023 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced that the first patient has been dosed in the Phase 1 trial of BI 771716 for the treatment of geographic atrophy (GA).
  • Licensed to Boehringer Ingelheim, BI 771716 is a highly specific antibody fragment of reduced size, enabling an optimized penetration through all retinal layers to the most critical target site driving GA disease pathology.
  • More than 5 million people worldwide suffer from GA, of which more than 40% are legally blind.
  • GA worsens with age, affecting 1 in 29 people above the age of 75 and 1 in 4 people above 90.

CDR-Life Presents Findings from Two Studies in Preparation of Phase 1 Trial with Immunotherapy CDR404 for Treatment of Solid Tumors at SITC 2023

Retrieved on: 
Friday, November 3, 2023
TCGA, TCE, CD3, QSP, SITC, Immunotherapy, Fragment crystallizable region, Database, Immunohistochemistry, Epithelium, Messenger, Annual general meeting, Society, Patient, Vaccine, Medical imaging

ZÜRICH, Switzerland, Nov. 03, 2023 (GLOBE NEWSWIRE) -- CDR-Life Inc., in the run-up to initiation of its first Phase 1 clinical trial, presented two posters for CDR404, a first-of-its-kind, antibody-based, bivalent & bispecific MAGE-A4 T-cell engager (TCE) targeting MAGE-A4, an intracellular cancer protein with expression in several frequent and difficult to treat solid tumors, at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting.

Key Points: 
  • The demonstration of high MAGE-A4 protein expression in SQ-NSCLC and potent preclinical cytotoxicity of CDR404, highlights the therapeutic promise of CDR404 in HLA-A*02:01+ patients with SQ-NSCLC.
  • “These milestones underscore the continued advancement of CDR404’s potential as an off-the-shelf precision immunotherapy for MAGE-A4+ solid tumors.
  • Treatment with four different doses of CDR404 induced complete tumor regression in the in vivo SQ-NSCLC NCI-H1703 xenograft model.
  • The QSP model predicted doses of CDR404 which might have the most favorable benefit-risk profile for patients in the Phase 1 trial.

CDR-Life Presents Precise Tumor and Patient Selection for CDR404: First-of-its-Kind Dual MAGE-A4 T-cell Engager, at ESMO Congress 2023

Retrieved on: 
Monday, October 23, 2023
Bispecific monoclonal antibody, The Cancer Genome Atlas, Adenocarcinoma, TCGA, TCE, NSCLC, ESMO, IHC, HPV, Data, Head, Bladder cancer, Neck, Neoplasm, Histology, Messenger, Bivalent, Patient, HLA, Vaccine

ZÜRICH, Switzerland, Oct. 23, 2023 (GLOBE NEWSWIRE) -- CDR-Life Inc. presented findings on tumor target expression and precise patient selection for the upcoming Phase 1 trial of CDR404 (Abstract 200P), a first-of-its-kind bispecific and bivalent antibody fragment-based T-cell engager (TCE) targeting MAGE-A4, an intracellular protein which is presented on HLA-A*02:01 on the surface of cancer cells, at the ESMO Congress 2023, occurring October 20-24 in Madrid, Spain.

Key Points: 
  • The key objective of this study was for CDR-Life to explore MAGE-A4 expression levels in solid tumors using The Cancer Genome Atlas (TCGA) mRNA dataset.
  • In addition, subgroups of high MAGE-A4 expression were present across a wide range of solid cancers including lung adenocarcinoma, ovarian and gastric cancers.
  • “CDR404 is a novel, bispecific and bivalent T-cell engager differentiated from previous solid tumor T-cell engagers targeting MAGE-A4 in the clinic.
  • The MAGE-A4 mRNA distribution profiles across multiple tumor types indicate, that a tumor MAGE-A4 assay will be indispensable for trial screening.

CDR-Life Announces Second Milestone Achievement with Boehringer Ingelheim in Developing Antibody Fragment-based Therapeutics for Geographic Atrophy

Retrieved on: 
Wednesday, August 2, 2023
Retina, Boehringer Ingelheim, MHC, Geographic atrophy, Partnership, Vance DeGeneres, Paratriathlon, GA, AMD, Vaccine

ZÜRICH, Switzerland, Aug. 02, 2023 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced a milestone payment triggered by the achievement of a development milestone with a partnered antibody fragment-based drug candidate that could significantly slow down the progression of geographic atrophy (GA).

Key Points: 
  • ZÜRICH, Switzerland, Aug. 02, 2023 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced a milestone payment triggered by the achievement of a development milestone with a partnered antibody fragment-based drug candidate that could significantly slow down the progression of geographic atrophy (GA).
  • Boehringer Ingelheim and CDR-Life entered a collaboration and licensing agreement in May 2020 and announced the selection of an antibody fragment-based therapeutic candidate in September 2021.
  • GA is a progressive, irreversible retinal disease and one of the leading causes of blindness in people over 65 years of age.
  • The company’s first of several therapeutic candidates in development, CDR404, targets MAGE-A4 and is anticipated to enter the clinic in 2024.

CDR-Life Announces the Appointment of Nicole Onetto, MD, MSc, to Board of Directors

Retrieved on: 
Thursday, December 8, 2022
Roche, Breast cancer, ImmunoGen, Pediatrics, Master of Science, Acquisition, BMS, OSI Pharmaceuticals, Partnership, Bristol Myers Squibb, Ovarian cancer, YM Biosciences, Safety, University, Cancer, Biotechnology, ZymoGenetics, Ontario Institute for Cancer Research, Doctor of Philosophy, Genentech, MD, Geographic atrophy, MHC, Drug development, Severe cognitive impairment, Therapy, Gilead Sciences, Boehringer Ingelheim, Hematology, Senior, Patient, Fine chemical, Pharmaceutical industry, Medicine, Paclitaxel, Pharmacology

We are very pleased to welcome Dr. Nicole Onetto to our Board.

Key Points: 
  • We are very pleased to welcome Dr. Nicole Onetto to our Board.
  • Dr. Onetto previously worked in senior management positions at Bristol Myers Squibb (BMS), Nexstar Pharmaceuticals, and Gilead Sciences.
  • Dr. Onetto holds a medical degree from the University of Paris and a Master of Pharmacology from the University of Montréal.
  • CDR-Life has a strategic partnership with Boehringer Ingelheim to develop an antibody fragment-based therapeutic for geographic atrophy, a leading cause of blindness worldwide.

CDR-Life to Participate in the 2022 Jefferies London Healthcare Conference

Retrieved on: 
Tuesday, November 1, 2022
MHC, Conference, GLOBE, Severe cognitive impairment, Biotechnology, Therapy, Company, Geographic atrophy, Partnership, Boehringer Ingelheim, Pharmaceutical industry, Fine chemical, Vaccine

ZRICH, Switzerland, Nov. 01, 2022 (GLOBE NEWSWIRE) -- CDR-Life Inc ., a biotechnology company pioneering a new and differentiated class of highly tumor-selective immuno-oncology therapeutics based on its proprietary antibody-based MHC-targeting T cell engager technology, today announced that Christian Leisner, Chief Executive Officer and Bjrn Peters, Chief Business Officer, will participate in one-on-one meetings at the upcoming Jefferies London Healthcare Conference from November 15-17, 2022 in London, United Kingdom.

Key Points: 
  • ZRICH, Switzerland, Nov. 01, 2022 (GLOBE NEWSWIRE) -- CDR-Life Inc ., a biotechnology company pioneering a new and differentiated class of highly tumor-selective immuno-oncology therapeutics based on its proprietary antibody-based MHC-targeting T cell engager technology, today announced that Christian Leisner, Chief Executive Officer and Bjrn Peters, Chief Business Officer, will participate in one-on-one meetings at the upcoming Jefferies London Healthcare Conference from November 15-17, 2022 in London, United Kingdom.
  • CDR-Life is a privately held, biotherapeutics company leveraging its unique antibody technology, M-gager, to target highly cancer-specific intracellular proteins presented on the major histocompatibility complex (MHC).
  • CDR-Life is advancing a robust pipeline of novel fully cancer-directed T cell engagers in various solid tumors.
  • CDR-Life has a strategic partnership with Boehringer Ingelheim to develop an antibody fragment-based therapeutic for geographic atrophy, a leading cause of blindness worldwide.

CDR-Life Announces Appointment of Swethajit Biswas, MD, as Chief Medical Officer

Retrieved on: 
Tuesday, August 23, 2022
Partnership, University, Royal college, Cancer, F.X. v The Clinical Director of Central Mental Hospital and Another, FRCP, National Health Service, Time, Doctor of Philosophy, Multiple myeloma, Severe cognitive impairment, GSK, Royal College of Physicians, Geographic atrophy, LinkedIn, Newcastle, MHC, Antigen, NHS, BCMA, GlaxoSmithKline, Brain, GLOBE, Company, Biotechnology, Therapy, Twitter, Boehringer Ingelheim, Cancer/testis antigens, Sarcoma, Oncology, TCR, Patient, Lymphoma, Fine chemical, Pharmaceutical industry, MD

Prior to joining CDR-Life, Dr. Biswas was a Development Leader for MAGE-A4+ autologous cell therapies at Adaptimmune Therapeutics plc, progressing afamitresgene autoleucel through an accelerated approval submission pathway.

Key Points: 
  • Prior to joining CDR-Life, Dr. Biswas was a Development Leader for MAGE-A4+ autologous cell therapies at Adaptimmune Therapeutics plc, progressing afamitresgene autoleucel through an accelerated approval submission pathway.
  • He also held an academic position as a Clinical Senior Lecturer in medical oncology at Newcastle Universitys Northern Institute for Cancer Research (NICR) from 2009 to 2013.
  • Dr. Biswas received his medical degree from Sheffield University Medical School and his DPhil from the University of Oxford.
  • For more information, please visit cdr-life.com and follow the Company on Twitter and LinkedIn.